Sinopharm Group Co (HK:1099) has released an update.
Sinopharm Group Co. Ltd. successfully conducted its annual general meeting along with class meetings for H and domestic shareholders, where all proposed resolutions were overwhelmingly approved via polling. Key approvals included the company’s 2023 financial reports, auditors’ report, profit distribution plan, and final dividend payment. Additionally, the board and supervisory committee’s remuneration for the upcoming year received shareholder sanction.
For further insights into HK:1099 stock, check out TipRanks’ Stock Analysis page.
